IL122338A0 - Methods of inhibiting phagocytosis - Google Patents

Methods of inhibiting phagocytosis

Info

Publication number
IL122338A0
IL122338A0 IL12233896A IL12233896A IL122338A0 IL 122338 A0 IL122338 A0 IL 122338A0 IL 12233896 A IL12233896 A IL 12233896A IL 12233896 A IL12233896 A IL 12233896A IL 122338 A0 IL122338 A0 IL 122338A0
Authority
IL
Israel
Prior art keywords
methods
inhibiting phagocytosis
phagocytosis
inhibiting
Prior art date
Application number
IL12233896A
Original Assignee
Univ Pennsylvania Center For T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania Center For T filed Critical Univ Pennsylvania Center For T
Publication of IL122338A0 publication Critical patent/IL122338A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
IL12233896A 1995-06-07 1996-06-07 Methods of inhibiting phagocytosis IL122338A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48353095A 1995-06-07 1995-06-07
PCT/US1996/010494 WO1996040199A1 (en) 1995-06-07 1996-06-07 Methods of inhibiting phagocytosis

Publications (1)

Publication Number Publication Date
IL122338A0 true IL122338A0 (en) 1998-04-05

Family

ID=23920431

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12233896A IL122338A0 (en) 1995-06-07 1996-06-07 Methods of inhibiting phagocytosis

Country Status (6)

Country Link
EP (1) EP0831875A4 (en)
JP (1) JPH11507824A (en)
AU (1) AU723595B2 (en)
CA (1) CA2223402C (en)
IL (1) IL122338A0 (en)
WO (1) WO1996040199A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
GB9822763D0 (en) * 1998-10-20 1998-12-16 Univ Sheffield Immunoglobin variant
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
WO2002089832A2 (en) * 2001-05-09 2002-11-14 Alk-Abelló A/S Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
WO2005049838A2 (en) 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
TW200808360A (en) 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111105A (en) * 1993-09-30 2009-05-04 Univ Pennsylvania Use of a molecule capable of inhibiting the expression of syk kinase to prepare a pharmaceutical composition for inhibiting phagocytosis
US5641863A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
WO1995014790A1 (en) * 1993-11-23 1995-06-01 Ciba Corning Diagnostics Corp. Use of antisense oligomers in a process for controlling contamination in nucleic acid amplification reactions

Also Published As

Publication number Publication date
JPH11507824A (en) 1999-07-13
EP0831875A4 (en) 2002-07-31
WO1996040199A1 (en) 1996-12-19
AU6386996A (en) 1996-12-30
CA2223402C (en) 2012-07-31
EP0831875A1 (en) 1998-04-01
AU723595B2 (en) 2000-08-31
CA2223402A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
PL322277A1 (en) Derivatives of pyrazol-4-ylobenzoyl
PL327569A1 (en) Promedications of thrombosin inhibitors
PL324451A1 (en) Derivatives of diphenylmethylenepiperidine
PL327067A1 (en) Method of obtaining pure melamine
PL323236A1 (en) Method of obtaining lerkanipidin chlorchydride
IL116924A (en) Preparation of n-aryl - and n-hetarylhydroxylamines
GB9624854D0 (en) Structural part of hf-tight housings
IL122338A0 (en) Methods of inhibiting phagocytosis
IL123320A0 (en) Detection of hypoprathyroidism
IL118574A0 (en) Methods of inhibiting melanoma
PL320114A1 (en) Phenyl-substituted fluoroderivatives of 4-azasteroides
PL327147A1 (en) Method of obtaining dihydropyrimidinones
PL326080A1 (en) Short forms of chemokin beta-8
ZA969429B (en) Amidinohydrazones of ketones
IL117036A0 (en) Methods of inhibiting effects of il-6
PL326978A1 (en) Method of obtaining dioxyaza bicyclohexanes
PL323148A1 (en) Esters of crabapenemes
IL117786A (en) Preparation of alpha-bisoximes
EG20782A (en) Process of preparation streptogramines
PL312826A1 (en) Method of obtaining dilthiazeme
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
PL323141A1 (en) Esters of crabapenemes
IL117365A0 (en) Treatment of eczema
GB9504913D0 (en) Production of trialkoxypropane
ZA962440B (en) Destressing of railtracks